Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms
- 1Cancer Molecular Diagnostics, St. James’s Hospital, 8 Dublin Dublin, Ireland
Abstract
BCR::ABL1 negative myeloproliferative neoplasms (MPN) are driven predominantly by somatic mutations in JAK2, CALR, and MPL, which underpin diagnosis, prognostication, and measurable residual disease (MRD) monitoring. Advances in molecular assays have improved sensitivity for detecting canonical drivers and additional mutations across the MPN spectrum. In this review we evaluate current and emerging molecular methodologies for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We review the utility of PCR-based approaches, including allele-specific PCR, real-time quantitative PCR, and droplet digital PCR (ddPCR). Advances in ddPCR demonstrate precision and lower limits of detection for JAK2 V617F, CALR, and non-driver mutations, thus supporting the expanding role of ddPCR in MRD monitoring and relapse prediction. Recent advances in NGS techniques provide targeted profiling, enabling identification of possible co-occurring driver mutations and additional mutations associated with disease progression, treatment resistance, and leukemic transformation. Collectively, emerging workflows complement established gold-standard methodologies, while offering enhanced analytical performance and deeper pathological insight across the MPN spectrum. Optimal method selection requires balancing assay sensitivity, cost, and clinical utility. Advances in ddPCR and NGS methodologies have applicability for MRD monitoring in MPN and are powerful tools for detection of heterogenous and co-occurrent mutations across the MPN spectrum.
Related
- Post-transplant monitoring of NGS-based measurable residual disease and donor chimerism as a prognostic tool in older patients with AML/MDS
- Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach
- Next-generation digital polymerase chain reaction assay for BCR::ABL1 in chronic myeloid leukemia: comprehensive validation for standardized measurable residual disease detection
- Allele burden expansion in JAK2 V617F and CALR ‐mutated myeloproliferative neoplasms predicts disease progression and is associated with anagrelide treatment
- The JAK2 V617F revolution in myeloproliferative neoplasms.
BibTeX
@article{markey2026measurable,
title = {{Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms}},
author = {Gary E. Markey and Stephen E. Langabeer},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18203397},
url = {https://www.mdpi.com/2072-6694/18/20/3397},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms
AU - Gary E. Markey
AU - Stephen E. Langabeer
PY - 2026
DA - 2026/10/20
JO - Cancers
DO - 10.3390/cancers18203397
UR - https://www.mdpi.com/2072-6694/18/20/3397
AB - BCR::ABL1 negative myeloproliferative neoplasms (MPN) are driven predominantly by somatic mutations in JAK2, CALR, and MPL, which underpin diagnosis, prognostication, and measurable residual disease (MRD) monitoring. Advances in molecular assays have improved sensitivity for detecting canonical drivers and additional mutations across the MPN spectrum. In this review we evaluate current and emerging molecular methodologies for polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). We review the utility of PCR-based approaches, including allele-specific PCR, real-time quantitative PCR, and droplet digital PCR (ddPCR). Advances in ddPCR demonstrate precision and lower limits of detection for JAK2 V617F, CALR, and non-driver mutations, thus supporting the expanding role of ddPCR in MRD monitoring and relapse prediction. Recent advances in NGS techniques provide targeted profiling, enabling identification of possible co-occurring driver mutations and additional mutations associated with disease progression, treatment resistance, and leukemic transformation. Collectively, emerging workflows complement established gold-standard methodologies, while offering enhanced analytical performance and deeper pathological insight across the MPN spectrum. Optimal method selection requires balancing assay sensitivity, cost, and clinical utility. Advances in ddPCR and NGS methodologies have applicability for MRD monitoring in MPN and are powerful tools for detection of heterogenous and co-occurrent mutations across the MPN spectrum.
SN - 2072-6694
ER -